Bristol Myers Squibb (NYSE:BMY) has unveiled plans to invest approximately $2.3 billion in a new manufacturing campus at Generation Park in Houston, Texas, as the pharmaceutical group expands its production capabilities in the United States.
The project is expected to create nearly 500 permanent skilled positions alongside approximately 2,000 construction and other indirect jobs between 2027 and 2030.
Spanning roughly 600,000 square feet, the proposed facility will be designed to manufacture several types of medicines and provide Bristol Myers Squibb with additional flexibility as its development pipeline evolves.
New facility to manufacture multiple drug types
The Houston site will operate as a modular, multi-modal manufacturing campus capable of producing small molecules, biologics and antibody-drug conjugates.
Its modular structure is intended to allow Bristol Myers Squibb to expand or reconfigure production capacity depending on future commercial requirements and changes within its pharmaceutical pipeline.
Planned positions at the campus include operations technicians, production specialists, maintenance and engineering professionals, quality control and quality assurance experts, as well as site management and administrative roles.
The company said the facility has been designed with the ability to expand beyond its initial scale and capabilities over time.
Investment forms part of $40 billion U.S. commitment
The Houston project is part of Bristol Myers Squibb’s broader commitment to invest $40 billion over five years in U.S.-based research and development, technology and domestic manufacturing.
The company invested approximately $10 billion in research and development during 2025 alone.
Christopher Boerner, Ph.D., Board Chair and CEO of Bristol Myers Squibb, said: “As part of our $40 billion commitment to the United States, we’re building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs.”
The latest project therefore represents a significant component of the company’s strategy to expand its domestic pharmaceutical manufacturing footprint while supporting future product development.
Houston selected following competitive site review
Bristol Myers Squibb chose Generation Park after evaluating several potential locations across the central and eastern United States.
Factors influencing the decision included Houston’s available life sciences workforce, local incentives, access to utilities and transportation infrastructure, and the broader business environment.
The company already has an established presence in Texas. Bristol Myers Squibb currently works with a contract manufacturer in the state for commercial and clinical trial production and operated through 250 clinical trial sites across Texas during 2025.
The planned $2.3 billion campus will substantially deepen that presence, while giving Bristol Myers Squibb a flexible manufacturing platform capable of supporting multiple drug technologies and adapting to future scientific and commercial requirements.
Bristol Myers Squibb stock price
